Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Skin Care Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,514,306

1,058 payments

Through program year 2025, Skin Care Research LLC is reported as receiving $1,514,306 in research payments, across 1,058 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $81,505 38
2024 Research $173,459 250
2023 Research $324,127 463
2022 Research $256,231 111
2021 Research $284,947 87
2020 Research $275,892 78
2019 Research $118,145 31

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $592,647 209 payments
  2. AbbVie, Inc. $536,935 223 payments
  3. Dermavant Sciences, Inc. $151,110 568 payments
  4. Acrotech Biopharma LLC $91,365 18 payments
  5. Eli Lilly and Company $42,751 11 payments
  6. Sanofi US Services Inc. $36,831 12 payments
  7. Endo Pharmaceuticals Inc. $21,418 7 payments
  8. Galderma Research & Development, LLC $21,112 4 payments
  9. Bausch Health US, LLC $20,138 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2A Randomized Doubleblind Placebo Controlled Study Investigating the Safety of Ritlecitinib Pf06651600 in Adult Participants With Alopecia Areata $158,005 60 payments
  2. Abrocitinib Expanded Access Protocol for the Treatment of Adolescents and Adults With Moderate to Severe Atopic Dermatitis $91,568 25 payments
  3. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy $83,900 28 payments
  4. An Open Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis $81,809 166 payments
  5. M18-891 $80,695 16 payments
  6. 246-13651-302 $76,686 16 payments
  7. A Randomized Doubleblind Placebocontrolled Study to Demonstrate the Efficacy and Longterm Safety of Pf04965842 With Topical Corticosteroids in Adult Patients With Moderatetosevere Atopic Dermatitis $76,246 15 payments
  8. A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa $64,830 12 payments
  9. A Phase 3 Randomized Doubleblind Vehiclecontrolled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction With Crisaborole Ointment 2 Once Daily Over 52 Weeks in Pediatric and Adult Participants Ages 3 Months and Older With Mildtomoderate Atopic Dermatitis Who Responded to Twice Daily Crisaborole Ointment 2 Treatment $64,070 21 payments
  10. A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) $62,082 51 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record